Japan to file criminal complaint against Novartis (Update)

Japan's health ministry plans to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, an official said Wednesday.

Novartis Pharma KK has been under fire since a university said the data in clinical studies might have been skewed to promote Valsartan.

Health Minister Norihisa Tamura has characterised as "extremely regrettable" the incident in which an employee of the world's number two drug maker hid his affiliation during a medical study into the effects of the drug, which is used to lower blood pressure.

"We will take some action (against Novartis) as soon as we have completed arrangements," said the official at the ministry's compliance division.

"But it is technically difficult to do it today as the hour is getting late," he told AFP late Wednesday. "We may continue making such arrangements tomorrow."

Kyodo news agency reported earlier the ministry was to file a criminal charge against Novartis' local arm on Wednesday.

A Novartis spokesman in Switzerland said the company "is aware of the media speculation but has not received any official notification from the relevant authorities in Japan."

Under Japan's pharmaceutical law, anyone found guilty of exaggerated advertising can be punished with up to two years in prison or a fine of as much as two million yen ($19,400).

It would be the first time a criminal complaint has been filed in Japan over exaggerated pharmaceutical advertising, Kyodo said, quoting ministry officials.

A ministry panel of experts concluded in September that Novartis Pharma KK should be held responsible for studies at various universities that used manipulated data on the drug.

The studies suggested the drug—sold under the name Diovan in Japan and licensed for use in more than 100 countries—had some prophylactic effect on strokes and angina.

The firm used data from the studies to market its drug, playing up its supposed additional benefits.

Novartis has maintained that the company had no knowledge of the wrongdoing, in which an ex-employee allegedly failed to disclose his affiliation with Novartis during various academic studies in which incomplete clinical data were used.

The worker and other researchers involved in studies have denied to the panel that they manipulated the data.

Novartis Pharmaceuticals chief David Epstein has apologised for the concern the incident caused, but did not say that the company played any role in the allegations.

Tokyo's Jikei University School of Medicine has retracted research that appeared in respected medical journal The Lancet six years ago due to data fabrication.

Kyoto Prefectural University of Medicine also concluded that its studies on the drug used incomplete clinical data.

Chiba University said in December it could not find intentional data fabrication but researchers failed to disclose 91 million yen ($880,000) in scholarship donations from the pharmaceutical company in the three years from 2007 to 2009.

add to favorites email to friend print save as pdf

Related Stories

Japan to seek criminal prosecution of Novartis

Dec 18, 2013

Japan's health ministry intends to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged fabrication of drugs data, a report said Wednesday.

Britain snubs costly Novartis blood cancer drug

Feb 13, 2013

British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

15 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

15 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

16 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments